ONCAlert | Upfront Therapy for mRCC
Videos  >  

Evaluating the Role of CAR T-Cell Therapy in Relapsed/Refractory DLBCL

Karl M. Kilgore, PhD
Published Online:9:26 PM, Tue February 11, 2020

Karl M. Kilgore, PhD, senior research scientist, Avalere Health, discusses the role of chimeric antigen receptor (CAR) T-cell therapy as treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and where this option might fit into the landscape in the future.

Based on real-world data of the approved CAR T-cell therapies in DLBCL, Kilgore says the data are fairly optimistic in this patient population. There are not many treatment options available, and recent data have demonstrated CAR T cells are effective in this population, even in the patients who are older and have multiple comorbidities.

Physicians could consider CAT T-cell therapy a viable option for patients with relapsed/refractory DLBCL and as a viable treatment alternative in select patients. In the future, this therapy may even move earlier on in the course of treatment, Kilgore says.

<< View more resources and information regarding DLBCL
Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.